Rengyun Liu

sun yat-sen university

H指数:28

被引数:4,112

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alterations in gut microbiota and metabolic profiling are associated with papillary thyroid cancer and BRAFV600E mutation

肠道微生物群和代谢谱的异常与乳头状甲状腺癌及BRAFV600E突变相关

Endocrine

IF2.9

2026-04-010

PRE

DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer

DNA高甲基化抑制甲状腺过氧化物酶表达，并可能成为甲状腺癌有前景的诊断标志物

Thyroid

IF6.7

2026-01-010

PRE

DDX21 Links BRAF V600E and TERT to Promote Thyroid Cancer Progression

Ddx21连接BRAF(V600E)和TERT以促进甲状腺癌进展

Thyroid

IF6.7

2026-01-010

PRE

Erianin induces apoptosis of thyroid cancer cells via TNF signaling pathway

Erianin 通过 TNF 信号通路诱导甲状腺癌细胞凋亡。

European Journal of Pharmacology

IF4.7

2025-09-160

PRE

High Prevalence of TBC1D12 5′UTR Mutations in Anaplastic Thyroid Cancer

THYROID

IF6.7

2025-01-010

PRE

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

天然免疫激活联合PD-1/PD-L1阻断治疗结直肠癌的细胞机制

MOLECULAR CANCER

IF33.9

2024-11-120

OAAI

TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer

CANCER CELL INTERNATIONAL

IF6

2024-08-031

OAAI

The genetic duet of concurrent RASAL1 and PTEN alterations promotes cancer aggressiveness by cooperatively activating the PI3K-AKT pathway

MOLECULAR ONCOLOGY

IF4.5

2024-07-200

OAAI

Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma

PLK1在TERT启动子突变型肝癌中的靶向治疗作用

CLINICAL AND TRANSLATIONAL MEDICINE

IF6.8

2024-05-200

OAAI

Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer

甲状腺乳头状癌中常见基因突变和TERT启动子甲基化相结合的危险分层

ENDOCRINE

IF2.9

2024-02-143

PRE

TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer

FRONTIERS IN ONCOLOGY

IF3.3

2024-01-196

OAAI

Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2023-12-193

PRE

Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways

THYROID

IF6.7

2023-12-0112

PRE

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer

BMC CANCER

IF3.4

2023-04-201

OAAI

STRA6 Promotes Thyroid Carcinoma Progression via Activation of the ILK/AKT/mTOR Axis in Cells and Female Nude Mice

ENDOCRINOLOGY

IF3.3

2023-01-022

Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability

ONCOGENE

IF7.3

2022-10-1718

OAAI

Effect of Inactivated SARS-CoV-2 Vaccine on Thyroid Function and Autoimmunity Within 28 Days After the Second Dose

THYROID

IF6.7

2022-09-016

PRE

Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer

ONCOGENE

IF7.3

2022-03-1218

PRE

METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease

MOLECULAR THERAPY

IF12

2022-02-0162

OAAI

BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer

BRAF V600E状态可显著区分乳头状甲状腺癌的淋巴结转移相关死亡风险

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2021-07-1740

Rengyun Liu

个人简介

教育背景

工作经历

荣誉奖项

研究方向